University of Florida College of Medicine /ID# 278348, Gainesville
Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623, Orlando
Florida Cancer Specialists - North /ID# 278626, St. Petersburg
și încă 1

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Femei · Actualizat 22 sept. 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Broward Health Medical Center, Fort Lauderdale
Florida Cancer Specialist- South, Fort Myers
Baptist MD Anderson Cancer Center, Jacksonville
și încă 5

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Moffitt, Tampa

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07213791

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sylvester Comprehensive Cancer Center, Miami
Sara Cannon Research Institute Lake Nona, Orlando
Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT05983432

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Florida Cancer Specialists - Lake Nona, Orlando

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07109726

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Femei · Actualizat 17 sept. 2026 · NCT05316129

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Mount Sinai Cancer Center ( Site 0029), Miami Beach
Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 17 sept. 2026 · NCT07318558

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT07487168

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Advent Health, Orlando

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 15 sept. 2026 · NCT06915025

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Florida Cancer Specialists & Research Institute, Fort Myers
Sylvester Comprehensive Cancer Center, Miami
Mount Sinai Comprehensive Cancer Center, Miami Beach
și încă 1

În curs de recrutareFaza 2

Vârste de la 18 la 99 · Femei · Actualizat 15 sept. 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Brcr Global, Miramar
Sarasota Memorial Health Care System, Sarasota

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 15 sept. 2026 · NCT07214779

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Cleveland Clinic Foundation - Florida, Weston

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 14 sept. 2026 · NCT04575935

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Mayo Clinic Jacksonville, Jacksonville
University of Miami Sylvester Comprehensive Cancer Center, Miami
Advent Health Cancer Institute, Orlando
și încă 1

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Femei · Actualizat 14 sept. 2026 · NCT06787612

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Memorial Healthcare System, Hollywood
The Oncology Institute of Hope & Innovation, Lakeland

În curs de recrutareStudiu observațional

Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT05059444

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

University of Miami, Miami
Sarah Cannon Research Institute - Lake Nona Florida, Orlando

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 10 sept. 2026 · NCT06293898

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Mt. Sinai Comprehensive Cancer Center, Miami
Sarasota Memorial Health Care System, Sarasota

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 9 sept. 2026 · NCT07225270

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Femei · Actualizat 3 sept. 2026 · NCT07755436

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Mount Sinai Braman Comprehensive Cancer Center ( Site 0078), Miami Beach
Sarasota Memorial Hospital ( Site 0075), Sarasota
Florida Cancer Specialists East ( Site 7000), West Palm Beach

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 3 sept. 2026 · NCT06824467

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Florida Cancer Specialists, Orlando

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 27 aug. 2026 · NCT07186842

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

AdventHealth Cancer Institute, Orlando
Sarasota Memorial Healthcare System, Sarasota
Women's Cancer Associates with Women's Care Florida, St. Petersburg

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Femei · Actualizat 26 aug. 2026 · NCT05281471

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Moffitt Cancer Center, Tampa

În curs de recrutareFaza 1

Vârste de 15 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT06276491

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

UF Health Cancer Institute - Gainesville, Gainesville

În curs de recrutareFaza 2/3

Vârste de 18 ani și peste · Toate sexele · Actualizat 19 aug. 2026 · NCT07001748

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

SCRI - Florida Cancer Specialists, Sarasota

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 18 aug. 2026 · NCT07470853

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
Florida Cancer Specialists - Bradenton Cancer Center, Bradenton
Morton Plant Hospital, Clearwater
și încă 25

În curs de recrutare

Vârste de la 35 la 50 · Femei · Actualizat 7 aug. 2026 · NCT04251052

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.